Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.61 |
| ▸ | HTR1A | P08908 | 13/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.61 |
| ▸ | HTR1D | P28221 | 2/20 | 0.48 |
| ▸ | HTR1B | P28222 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23228665 | 0.93 | HTR2C (0.67) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL11827483 | 0.87 | SLC6A2 (0.62) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL6926596 | 0.85 | SLC6A2 (0.64) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL5669748 | 0.81 | SLC6A2 (0.68) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL4142513 | 0.81 | HTR1A (0.59) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL23228697 | 0.80 | SLC6A2 (0.58) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL23228623 | 0.79 | SLC6A2 (0.61) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL330081 | 0.79 | HTR2C (1.00) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL29891667 | 0.79 | HTR2C (1.00) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL23228766 | 0.78 | SLC6A2 (0.59) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021070090-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |